Oppenheimer Asset Management Inc. Has $208,000 Stock Position in AdaptHealth Corp. (NASDAQ:AHCO)

Oppenheimer Asset Management Inc. increased its position in shares of AdaptHealth Corp. (NASDAQ:AHCO) by 49.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,783 shares of the company’s stock after purchasing an additional 6,879 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in AdaptHealth were worth $208,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of AHCO. Charles Schwab Investment Management Inc. boosted its position in shares of AdaptHealth by 21.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,040,947 shares of the company’s stock worth $7,589,000 after acquiring an additional 183,135 shares in the last quarter. Olympiad Research LP bought a new position in shares of AdaptHealth in the 4th quarter valued at $129,000. PNC Financial Services Group Inc. raised its holdings in shares of AdaptHealth by 6.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 24,504 shares of the company’s stock worth $179,000 after buying an additional 1,382 shares in the last quarter. Reinhart Partners LLC. lifted its position in shares of AdaptHealth by 3.6% during the 1st quarter. Reinhart Partners LLC. now owns 4,210,211 shares of the company’s stock worth $48,460,000 after buying an additional 144,516 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in AdaptHealth by 197.1% in the first quarter. GAMMA Investing LLC now owns 2,537 shares of the company’s stock valued at $29,000 after buying an additional 1,683 shares in the last quarter. 82.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at AdaptHealth

In other news, Director David Solomon Williams III sold 4,000 shares of AdaptHealth stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $11.26, for a total transaction of $45,040.00. Following the transaction, the director now owns 36,899 shares in the company, valued at $415,482.74. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.43% of the company’s stock.

Analyst Ratings Changes

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $13.00 target price on shares of AdaptHealth in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.70.

AdaptHealth Trading Down 0.4 %

NASDAQ AHCO opened at $11.25 on Monday. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -2.13, a price-to-earnings-growth ratio of 1.75 and a beta of 1.10. AdaptHealth Corp. has a twelve month low of $6.37 and a twelve month high of $11.90. The company has a quick ratio of 0.94, a current ratio of 1.15 and a debt-to-equity ratio of 1.38. The business’s fifty day moving average is $10.76 and its 200 day moving average is $10.44.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.06). AdaptHealth had a negative net margin of 21.20% and a positive return on equity of 9.58%. The firm had revenue of $805.98 million for the quarter, compared to analyst estimates of $802.62 million. During the same period in the previous year, the business posted $0.16 earnings per share. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. As a group, sell-side analysts expect that AdaptHealth Corp. will post 0.87 EPS for the current fiscal year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.